FDA grants priority review to supplemental Biologics License Application for pembrolizumab plus chemotherapy as first-line treatment of oesophageal and gastroeosophageal junction cancer

The application for use in locally advanced unresectable or metastatic disease is based on data from the Phase III KEYNOTE-590 trial, in which it was associated with improvements in overall and progression-free survival regardless of PD-L1 expression status and tumour histology.

Source:

Biospace Inc.